Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
250.68
+6.14 (2.51%)
At close: Aug 31, 2026, 4:00 PM EDT
251.00
+0.32 (0.13%)
Pre-market: Sep 1, 2026, 7:32 AM EDT
Jazz Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 20 analysts polled by S&P Global, Jazz Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $286.9. The average 1-year stock price forecast is 14.45% higher than the current stock price, while the lowest is $196 (-21.81%) and the highest is $322 (+28.45%).
Price Target: $286.9 (+14.45%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Jazz Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 10 | 10 | 11 | 11 |
| Buy | 5 | 6 | 7 | 7 | 7 | 7 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 17 | 19 | 19 | 20 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Buy Maintains $300 | Buy | Maintains | $300 | +19.67% | Sep 1, 2026 |
| Needham | Needham | Buy Reiterates $310 | Buy | Reiterates | $310 | +23.66% | Aug 31, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $277 → $299 | Buy | Reiterates | $277 → $299 | +19.28% | Aug 27, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $300 | Buy | Maintains | $300 | +19.67% | Aug 26, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $283 → $322 | Buy | Reiterates | $283 → $322 | +28.45% | Aug 26, 2026 |
Financial Forecast
Revenue This Year
4.72B
from 4.27B
Increased by 10.68%
Revenue Next Year
4.99B
from 4.72B
Increased by 5.64%
EPS This Year
25.03
from 8.38
Increased by 198.63%
EPS Next Year
25.77
from 25.03
Increased by 2.98%
EPS and Forward PE are based on non-GAAP adjusted numbers.